BRIEF

on Xenetic Biosciences, Inc. (NASDAQ:XBIO)

Xenetic Biosciences Reports Q1 2025 Financial Results

Stock price chart of Xenetic Biosciences, Inc. (EBR:XBIO) showing fluctuations.

Xenetic Biosciences Inc. disclosed its first-quarter financial results for 2025, emphasizing ongoing collaborations and development initiatives. The company, noted for its immuno-oncology technologies, continues to concentrate on the progression of its DNase I program towards an IND and forthcoming human studies for pancreatic carcinoma treatment. They concluded the quarter with $5.2 million in cash to support future operations.

Collaborations with partners like PeriNess Ltd. were highlighted, advancing DNase's potential for treating osteosarcoma and Ewing sarcoma. Additionally, progress was noted in preclinical studies concerning DNase I combinations with therapies for colorectal cancer. Financially, Q1 revealed a net loss of $0.9 million with a slight revenue increase of 16.1% to $0.6 million, while operational costs decreased due to prior executive departures.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Xenetic Biosciences, Inc. news